Orange County Business Journal (OCBJ) interviews Visionary Ventures managing partner Jeffry Weinhuff and a Flying L managing partner Bill Link about investing in ophthalmology.
In this week’s OIS Podcast, Dr. Ehsan Sadri speaks with Bob Dempsey who just assumed the CEO role for TearClear. Let’s hear how Bob’s experience taking Xiidra to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.
TearClear Completes Initial Close of $25MM Series B Financing led by Visionary Ventures, Bluestem Capital, and Flying L. Additionally, TearClear has appointed Robert Dempsey to the CEO role. Robert Dempsey and Bill Link were interviewed by Eyewire news about the latest financing and CEO appointment.
Q&A with Jeffry Weinhuff from Visionary Ventures on how life science investors view the current COVID-19 climate, what opportunities might arise, and what health care innovations are more important now more than ever.
Tarsus is a late clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives, starting with Demodex blepharitis. Tarsus is developing a pipeline of products, with the lead candidate, TP-03, in clinical development to treat Demodex blepharitis. TP-03 is a novel, topical ophthalmic drug that specifically targets the Demodex mite’s nervous system, thereby treating the underlying cause of disease.
Tarsus Pharmaceuticals completes $60MM Series B financing
TearClear aims to be the premier specialty pharmaceutical company assuring reliable delivery of preservative-free ophthalmic drugs from preserved multi-dose solutions.
Eye Drops Proven To Reverse Vision Loss In Clinical Trial
Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically significant improvement in distance-corrected near visual acuity of a 3-line or greater gain. In addition, CSF-1 demonstrated an exceptional safety and tolerability profile.
Jeff discusses the value of OIS for the venture community and the success of Visionary Ventures.
